Development and Validation of HPLC Method for Simultaneous Estimation of Minoxidil and Finasteride in Topical Solution

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This study developed and validated a reverse phase liquid chromatography method to accurately and reliably measure Minoxidil and Finasteride in bulk and marketed formulations.

This study reports that while topical minoxidil treatment showed a response in less than 40% of men after 24 weeks, oral finasteride stopped hair loss in over 80% of patients at 12 months; perceived sexual side effects of the latter may limit its use.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that low-level laser therapy was the most effective non-surgical treatment for androgenetic alopecia, although the overall quality of evidence supporting various therapies was generally low.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

In this study, most male patients with androgenic alopecia who transitioned from oral to topical finasteride with minoxidil maintained good hair density.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.